<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00129363</url>
  </required_header>
  <id_info>
    <org_study_id>SB 105517-396</org_study_id>
    <nct_id>NCT00129363</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety of Twice Daily Oral Carvedilol</brief_title>
  <official_title>A Multicenter, Open Label Extension Study to Evaluate the Safety of Twice Daily Oral Carvedilol in Pediatric Patients With Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaddy, Robert, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shaddy, Robert, M.D.</source>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the long-term safety of carvedilol in pediatric&#xD;
      patients with chronic heart failure, who completed the Pediatric Carvedilol Study 321.&#xD;
      Carvedilol will be provided as open-label therapy for a period of at least 6 months (or until&#xD;
      termination of the study) by SmithKline Beecham Corporation d/b/a GlaxoSmithKline (GSK) or&#xD;
      the University Sponsor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label, uncontrolled, extension study is designed to assess the long-term safety of&#xD;
      carvedilol in pediatric patients with heart failure and includes the following phases:&#xD;
&#xD;
        1. Screening Phase (coincides with the final maintenance Month 6 Visit in the 321 study&#xD;
&#xD;
        2. Down-/Up-titration Phase&#xD;
&#xD;
        3. Maintenance Phase&#xD;
&#xD;
        4. Down-titration&#xD;
&#xD;
        5. Follow-up&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dose tolerability</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>growth and development</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>physical exam (PE) including cardiopulmonary examination</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>blood pressure (BP), heart rate (HR), height (Ht) and weight [Wt] (including %)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>laboratory safety assessments</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>pregnancy test, if applicable</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>an echocardiographic measurement</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>reporting of all adverse events [AEs] (serious and non-serious)</measure>
  </primary_outcome>
  <enrollment type="Actual">75</enrollment>
  <condition>Congestive Heart Failure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients with chronic symptomatic congestive heart failure (CHF) due to&#xD;
             systemic ventricular systolic dysfunction, who are receiving standard heart failure&#xD;
             therapy and have successfully completed the maintenance phase of the Pediatric&#xD;
             Carvedilol Study 321.&#xD;
&#xD;
          -  Parent or guardian of patient able and willing to give written informed consent. The&#xD;
             written assent from children &gt; 9 years of age is also required.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A patient who, in the opinion of the investigator, would not benefit from open-label&#xD;
             carvedilol.&#xD;
&#xD;
          -  A patient who, in the opinion of the investigator, is incapable of cooperating with&#xD;
             the requirements of this study.&#xD;
&#xD;
          -  A patient treated with the following medications at the time of entry in the study:&#xD;
&#xD;
               -  Monoamine oxidase (MAO) inhibitors;&#xD;
&#xD;
               -  Calcium entry blockers;&#xD;
&#xD;
               -  Î±- blockers, or labetalol;&#xD;
&#xD;
               -  Disopyramide, flecainide, encainide, moricizine, propafenone;&#xD;
&#xD;
               -  Intravenous inotropes such as dobutamine or intravenous vasodilator agents such&#xD;
                  as amrinone or milrinone;&#xD;
&#xD;
               -  Intravenous CHF medications (e.g. diuretics, digoxin);&#xD;
&#xD;
               -  Beta-blockers, other than double-blind carvedilol.&#xD;
&#xD;
          -  Uncorrected primary obstructive or severe regurgitative valvular disease, nondilated&#xD;
             (restrictive) or hypertrophic cardiomyopathy, or significant systemic ventricular&#xD;
             outflow obstruction.&#xD;
&#xD;
          -  A patient with any of the following contra-indications to beta-blocker therapy:&#xD;
&#xD;
               -  Heart rate &lt; 2nd percentile for age;&#xD;
&#xD;
               -  Unacceptable blood pressure. Sitting (supine in infants) systolic blood pressure&#xD;
                  must be &gt; 85 mm Hg in teens; &gt;75 mm Hg in school-aged children; and &gt;65 mm Hg in&#xD;
                  infants;&#xD;
&#xD;
               -  Sick sinus syndrome, second or third degree atrioventricular (AV) block, unless&#xD;
                  treated with a permanent pacemaker;&#xD;
&#xD;
               -  History or current clinical evidence of moderate-to-severe obstructive pulmonary&#xD;
                  disease or reactive airway diseases (e.g., asthma) requiring therapy;&#xD;
&#xD;
               -  Unstable insulin-dependent diabetes mellitus.&#xD;
&#xD;
          -  Renovascular hypertension or evidence of pulmonary hypertension (pulmonary vascular&#xD;
             resistance index &gt; 6 Wood units m2) unresponsive to vasodilator agents such as oxygen,&#xD;
             nitroprusside, or nitric oxide&#xD;
&#xD;
          -  A patient with any one of these general exclusion criteria:&#xD;
&#xD;
               -  Significant renal (serum creatinine &gt; 2.0), hepatic (serum AST and/or ALT &gt; 3&#xD;
                  times upper limit of normal), gastrointestinal, or biliary disorders that could&#xD;
                  impair absorption, metabolism, or excretion of orally administered medications;&#xD;
&#xD;
               -  Endocrine disorders such as pheochromocytoma, active hyperthyroidism and&#xD;
                  untreated hypothyroidism;&#xD;
&#xD;
               -  Any illness other than heart failure that may limit survival within 1 year (e.g.&#xD;
                  neoplasm);&#xD;
&#xD;
               -  Girls of childbearing potential who are pregnant or sexually active and not&#xD;
                  taking adequate contraceptive precautions (e.g., intrauterine device [IUD] or&#xD;
                  oral contraceptives).&#xD;
&#xD;
          -  A patient who received any investigational drug within the preceding 30 days except&#xD;
             blinded medication in Pediatric Carvedilol Study 321. An investigational drug is&#xD;
             defined as any agent (placebo or drug) dispensed as part of a research study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Robert E Shaddy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mattel Children's Hospital at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital, Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.S. Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-2196</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110-1014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-1537</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Children's Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37332</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-7794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Childrens Hospital and Regional Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>August 8, 2005</study_first_submitted>
  <study_first_submitted_qc>August 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2005</study_first_posted>
  <last_update_submitted>December 24, 2008</last_update_submitted>
  <last_update_submitted_qc>December 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Robert E Shaddy, MD</name_title>
    <organization>The Children's Hospital of Philadelphia</organization>
  </responsible_party>
  <keyword>Adolescent</keyword>
  <keyword>Adrenergic alpha-Antagonists/therapeutic use</keyword>
  <keyword>Adrenergic alpha-Antagonists/pharmacokinetics</keyword>
  <keyword>Adrenergic alpha-Antagonists/administration &amp; dosage</keyword>
  <keyword>Adrenergic beta-Antagonists/therapeutic use</keyword>
  <keyword>Adrenergic beta-Antagonists/pharmacokinetics</keyword>
  <keyword>Adrenergic beta-Antagonists/administration &amp; dosage</keyword>
  <keyword>Age Factors</keyword>
  <keyword>Carbazoles/therapeutic use</keyword>
  <keyword>Carbazoles/administration &amp; dosage</keyword>
  <keyword>Child</keyword>
  <keyword>Child, Preschool</keyword>
  <keyword>Drug Administration Schedule</keyword>
  <keyword>Female</keyword>
  <keyword>Heart Failure, Congestive/etiology</keyword>
  <keyword>Heart Failure, Congestive/drug therapy</keyword>
  <keyword>Heart Failure, Congestive/blood</keyword>
  <keyword>Human</keyword>
  <keyword>Infant</keyword>
  <keyword>Infant, Newborn</keyword>
  <keyword>Male</keyword>
  <keyword>Natriuretic Peptide, Brain/blood</keyword>
  <keyword>Placebos</keyword>
  <keyword>Propanolamines/therapeutic use</keyword>
  <keyword>Propanolamines/administration &amp; dosage</keyword>
  <keyword>Prospective Studies</keyword>
  <keyword>Support, Non-U.S. Gov't</keyword>
  <keyword>Treatment Outcome</keyword>
  <keyword>Ventricular Dysfunction/drug therapy</keyword>
  <keyword>Ventricular Dysfunction/complications</keyword>
  <keyword>Ventricular Dysfunction/blood</keyword>
  <keyword>Ventricular Function/drug effects</keyword>
  <keyword>Ventricular Remodeling/drug effects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

